After-Hours Stock Movers:
Imara Inc. (Nasdaq: IMRA) 22.5% HIGHER; Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
Eargo, Inc. (NASDAQ: EAR) 8.4% LOWER; announced that the record date for its proposed rights offering is October 24, 2022 at 5:00 p.m. Eastern Time (the Record Date).
Travere Therapeutics, Inc. (NASDAQ: TVTX) 5.1% LOWER; announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy to be extended by three months.
Amprius Technologies (NYSE: AMPX) 1.6% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $14.00.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.